$TOVX
Theriva Biologics, Inc.

2018 Q4 Form 10-K Financial Statement

#000114420419010592 Filed on February 27, 2019

View on sec.gov

Income Statement

Concept 2018 Q4 2018 Q3 2018 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.202M $1.474M $1.430M
YoY Change -40.79% -13.8% -12.8%
% of Gross Profit
Research & Development $2.056M $16.00K $3.572M
YoY Change -45.32% -99.61% -26.06%
% of Gross Profit
Depreciation & Amortization $65.00K $67.00K $70.00K
YoY Change -18.75% 34.0% 16.67%
% of Gross Profit
Operating Expenses $3.258M $4.320M $5.003M
YoY Change -43.63% -26.05% -22.73%
Operating Profit -$4.320M -$5.003M
YoY Change -26.05% -22.73%
Interest Expense $47.00K $5.000K $10.00K
YoY Change 370.0%
% of Operating Profit
Other Income/Expense, Net $19.00K $631.0K $789.0K
YoY Change -99.78% -112.4% -63.47%
Pretax Income -$3.258M -$4.320M -$5.003M
YoY Change -43.66% -26.05% -22.73%
Income Tax
% Of Pretax Income
Net Earnings -$3.193M -$3.689M -$4.214M
YoY Change -213.55% -66.25% -2.34%
Net Earnings / Revenue
Basic Earnings Per Share -$1.12 -$0.93 -$1.05
Diluted Earnings Per Share -$1.12 -$0.93 -$1.05
COMMON SHARES
Basic Shares Outstanding 13.44M 4.028M 3.683M
Diluted Shares Outstanding 13.44M 4.028M 3.683M

Balance Sheet

Concept 2018 Q4 2018 Q3 2018 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $28.92M $9.549M $7.130M
YoY Change 68.91% -54.64% -46.71%
Cash & Equivalents $28.92M $9.549M $7.129M
Short-Term Investments
Other Short-Term Assets $593.0K $473.0K $540.0K
YoY Change -28.55% -62.46% -65.16%
Inventory
Prepaid Expenses $42.00K $230.0K $130.0K
Receivables
Other Receivables $0.00 $86.00K $0.00
Total Short-Term Assets $29.51M $10.11M $7.664M
YoY Change 64.47% -54.69% -48.63%
LONG-TERM ASSETS
Property, Plant & Equipment $607.0K $665.0K $731.0K
YoY Change -30.39% -29.26% -8.63%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $23.00K $23.00K $20.00K
YoY Change 15.0% 15.0% 0.0%
Total Long-Term Assets $630.0K $688.0K $754.0K
YoY Change -29.61% -29.07% -8.05%
TOTAL ASSETS
Total Short-Term Assets $29.51M $10.11M $7.664M
Total Long-Term Assets $630.0K $688.0K $754.0K
Total Assets $30.14M $10.80M $8.418M
YoY Change 60.0% -53.63% -46.52%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.034M $879.0K $1.217M
YoY Change -48.81% -20.09% -29.24%
Accrued Expenses $919.0K $1.485M $1.000M
YoY Change -39.78% -59.65% -66.22%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.384M $3.914M $4.319M
YoY Change -65.44% -77.67% -64.97%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $302.0K $329.0K $350.0K
YoY Change -24.5% -23.49% -22.22%
Total Long-Term Liabilities $302.0K $329.0K $350.0K
YoY Change -24.5% -23.49% -22.22%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.384M $3.914M $4.319M
Total Long-Term Liabilities $302.0K $329.0K $350.0K
Total Liabilities $3.686M $4.243M $4.672M
YoY Change -63.85% -73.61% -57.18%
SHAREHOLDERS EQUITY
Retained Earnings -$219.5M -$204.5M -$200.8M
YoY Change 13.03%
Common Stock $230.8M $200.8M $194.3M
YoY Change 19.77%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $17.07M -$3.733M -$6.487M
YoY Change
Total Liabilities & Shareholders Equity $30.14M $10.80M $8.418M
YoY Change 60.0% -53.63% -46.52%

Cashflow Statement

Concept 2018 Q4 2018 Q3 2018 Q2
OPERATING ACTIVITIES
Net Income -$3.193M -$3.689M -$4.214M
YoY Change -213.55% -66.25% -2.34%
Depreciation, Depletion And Amortization $65.00K $67.00K $70.00K
YoY Change -18.75% 34.0% 16.67%
Cash From Operating Activities -$3.290M -$3.599M -$4.310M
YoY Change -16.28% -20.38% -24.91%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change
Cash From Investing Activities $0.00 $0.00 $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 -400.0K 400.0K
YoY Change -103.23% -92.91%
NET CHANGE
Cash From Operating Activities -3.290M -3.599M -4.310M
Cash From Investing Activities 0.000 0.000 0.000
Cash From Financing Activities 0.000 -400.0K 400.0K
Net Change In Cash -3.290M -3.999M -3.910M
YoY Change -16.28% -152.07% 3810.0%
FREE CASH FLOW
Cash From Operating Activities -$3.290M -$3.599M -$4.310M
Capital Expenditures $0.00 $0.00 $0.00
Free Cash Flow -$3.290M -$3.599M -$4.310M
YoY Change -16.28% -16.69% -24.91%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
4000
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
230754000
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
192670000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-219461000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-194170000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
17068000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
-1496000
CY2018Q4 us-gaap Minority Interest
MinorityInterest
-2909000
CY2017Q4 us-gaap Minority Interest
MinorityInterest
-1914000
CY2018Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
14159000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
28918000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17116000
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
593000
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
827000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
29511000
CY2017Q4 us-gaap Assets Current
AssetsCurrent
17943000
CY2018Q4 syn Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
23000
CY2017Q4 syn Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
23000
CY2018Q4 us-gaap Assets
Assets
30141000
CY2017Q4 us-gaap Assets
Assets
18838000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1034000
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2020000
CY2018Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
1332000
CY2017Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
2074000
CY2018Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
99000
CY2017Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
90000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3384000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
9793000
CY2018Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
302000
CY2017Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
402000
CY2018Q4 us-gaap Liabilities
Liabilities
3686000
CY2017Q4 us-gaap Liabilities
Liabilities
10195000
CY2018Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
12296000
CY2017Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
12053000
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
15000
CY2017Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-3410000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
30141000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
18838000
CY2018 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5727000
CY2017 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7467000
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11844000
CY2017 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18784000
CY2018 us-gaap Operating Expenses
OperatingExpenses
17571000
CY2017 us-gaap Operating Expenses
OperatingExpenses
26251000
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
-17571000
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
-26251000
CY2018 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-4083000
CY2017 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-10738000
CY2018 us-gaap Investment Income Interest
InvestmentIncomeInterest
67000
CY2017 us-gaap Investment Income Interest
InvestmentIncomeInterest
21000
CY2018 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4150000
CY2017 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
10759000
CY2018 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-54000
CY2017 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-318000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-13367000
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-15174000
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-4.06
CY2017 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-6.23
CY2018 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
6232442
CY2017 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3553316
CY2018 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-25291000
CY2017 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-22136000
CY2017Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-8149000
CY2017Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6475000
CY2017Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5842000
CY2017Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5783000
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-3058000
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-4315000
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-10930000
CY2017Q4 us-gaap Net Income Loss
NetIncomeLoss
2812000
CY2017Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.70
CY2017Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.05
CY2017Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.90
CY2017Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.76
CY2017Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.70
CY2017Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.05
CY2017Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.90
CY2017Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.76
CY2017Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3355636
CY2017Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3514435
CY2017Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3665134
CY2017Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3673340
CY2017Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3355636
CY2017Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3514435
CY2017Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3665134
CY2017Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3673340
CY2018Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4990000
CY2018Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5003000
CY2018Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4320000
CY2018Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3258000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-2326000
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-4214000
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-3689000
CY2018Q4 us-gaap Net Income Loss
NetIncomeLoss
-3193000
CY2018Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.70
CY2018Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.05
CY2018Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.93
CY2018Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.12
CY2018Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.70
CY2018Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.05
CY2018Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.93
CY2018Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.12
CY2018Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3673340
CY2018Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3683384
CY2018Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4028304
CY2018Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13442104
CY2018Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3673340
CY2018Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3683384
CY2018Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4028304
CY2018Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13442104
CY2017Q4 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.35
CY2018Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
172900000
CY2017 syn Operating Loss Carryforwards Expire Date
OperatingLossCarryforwardsExpireDate
2037
CY2017 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.21
CY2018 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
-2818000
CY2017 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
-5267000
CY2018 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
-636000
CY2017 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
-613000
CY2018 us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
19000
CY2017 us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
-2000
CY2018 us-gaap Income Tax Reconciliation Nondeductible Expense Meals And Entertainment
IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment
3000
CY2017 us-gaap Income Tax Reconciliation Nondeductible Expense Meals And Entertainment
IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment
10000
CY2018 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
266000
CY2017 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
502000
CY2018 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-1051000
CY2017 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-4076000
CY2018 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
0
CY2017 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
21555000
CY2018 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-4217000
CY2017 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
12109000
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2017 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2018Q4 syn Deferred Tax Assets Stocks Issued For Services
DeferredTaxAssetsStocksIssuedForServices
1998000
CY2017Q4 syn Deferred Tax Assets Stocks Issued For Services
DeferredTaxAssetsStocksIssuedForServices
1730000
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
38000
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
164000
CY2018Q4 syn Deferred Tax Assets Stock Issued For Acquisition Of Program
DeferredTaxAssetsStockIssuedForAcquisitionOfProgram
1224000
CY2017Q4 syn Deferred Tax Assets Stock Issued For Acquisition Of Program
DeferredTaxAssetsStockIssuedForAcquisitionOfProgram
1202000
CY2018Q4 syn Deferred Tax Assets Stock Issued Forlicense Agreement
DeferredTaxAssetsStockIssuedForlicenseAgreement
1760000
CY2017Q4 syn Deferred Tax Assets Stock Issued Forlicense Agreement
DeferredTaxAssetsStockIssuedForlicenseAgreement
1947000
CY2018Q4 syn Deferred Tax Assets Stock Issued For Milestone Payment
DeferredTaxAssetsStockIssuedForMilestonePayment
278000
CY2017Q4 syn Deferred Tax Assets Stock Issued For Milestone Payment
DeferredTaxAssetsStockIssuedForMilestonePayment
301000
CY2018Q4 syn Deferred Tax Assets Tax Deferred Expense Amortizable License Fee
DeferredTaxAssetsTaxDeferredExpenseAmortizableLicenseFee
5000
CY2017Q4 syn Deferred Tax Assets Tax Deferred Expense Amortizable License Fee
DeferredTaxAssetsTaxDeferredExpenseAmortizableLicenseFee
6000
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
44512000
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
40248000
CY2018Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
49815000
CY2017Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
45598000
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
49815000
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
45598000
CY2018Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2017Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2018 us-gaap Profit Loss
ProfitLoss
-13421000
CY2017 us-gaap Profit Loss
ProfitLoss
-15492000
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
2074000
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
3409000
CY2018 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-234000
CY2017 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1688000
CY2018 syn Increase Decrease In Deposits And Other Assets
IncreaseDecreaseInDepositsAndOtherAssets
0
CY2017 syn Increase Decrease In Deposits And Other Assets
IncreaseDecreaseInDepositsAndOtherAssets
0
CY2018 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-987000
CY2017 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
27000
CY2018 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-607000
CY2017 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1101000
CY2018 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-742000
CY2017 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
1761000
CY2018 us-gaap Increase Decrease In Deferred Compensation
IncreaseDecreaseInDeferredCompensation
-90000
CY2017 us-gaap Increase Decrease In Deferred Compensation
IncreaseDecreaseInDeferredCompensation
-3000
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-17279000
CY2017 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20204000
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
29088000
CY2017 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
18477000
CY2018 us-gaap Cash Period Increase Decrease
CashPeriodIncreaseDecrease
11802000
CY2017 us-gaap Cash Period Increase Decrease
CashPeriodIncreaseDecrease
-1939000
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19055000
CY2018 us-gaap Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
9000
CY2017 us-gaap Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
0
CY2018 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
0
CY2017 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
166000
CY2018 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
0
CY2017 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
11953000
CY2018 syn Proceeds From Units Offering Net Of Issuance Cost
ProceedsFromUnitsOfferingNetOfIssuanceCost
16916000
CY2017 syn Proceeds From Units Offering Net Of Issuance Cost
ProceedsFromUnitsOfferingNetOfIssuanceCost
0
CY2018 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">Use of Estimates</div></div></div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; background: none;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Such estimates and assumptions impact, among others, the following: the estimated useful lives for property and equipment, fair value of warrants, preferred stock and stock options granted for services or compensation, respectively, estimates of the probability and potential magnitude of contingent liabilities, and the valuation allowance for deferred tax assets due to continuing and expected future operating losses.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; background: none;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of consolidated financial statements, which management considered in formulating its estimate could change in the near term due to one or more future confirming events. Accordingly, actual results could differ from those estimates.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2018Q4 us-gaap Equity Method Investment Ownership Percentage
EquityMethodInvestmentOwnershipPercentage
0.830
CY2018Q4 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
700000
CY2017Q4 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
700000
CY2018Q4 us-gaap Prepaid Expense Current And Noncurrent
PrepaidExpenseCurrentAndNoncurrent
46000
CY2017Q4 us-gaap Prepaid Expense Current And Noncurrent
PrepaidExpenseCurrentAndNoncurrent
46000
CY2018Q4 syn Accrued Vendor Payments
AccruedVendorPayments
150000
CY2017Q4 syn Accrued Vendor Payments
AccruedVendorPayments
193000
CY2018Q4 syn Accrued Manufacturing Costs
AccruedManufacturingCosts
83000
CY2017Q4 syn Accrued Manufacturing Costs
AccruedManufacturingCosts
661000
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
12000
CY2017 syn Deferred Tax Assets Federal And Statutory Income Tax Rate
DeferredTaxAssetsFederalAndStatutoryIncomeTaxRate
0.21
CY2018Q4 us-gaap Prepaid Insurance
PrepaidInsurance
419000
CY2017Q4 us-gaap Prepaid Insurance
PrepaidInsurance
351000
CY2018Q4 syn Prepaid Consulting Subscriptions And Other Expenses
PrepaidConsultingSubscriptionsAndOtherExpenses
132000
CY2017Q4 syn Prepaid Consulting Subscriptions And Other Expenses
PrepaidConsultingSubscriptionsAndOtherExpenses
290000
CY2018Q4 syn Prepaid Clinical Research Organizations Expense Current
PrepaidClinicalResearchOrganizationsExpenseCurrent
0
CY2017Q4 syn Prepaid Clinical Research Organizations Expense Current
PrepaidClinicalResearchOrganizationsExpenseCurrent
46000
CY2018Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
0
CY2017Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
46000
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1302000
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1301000
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
695000
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
429000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
607000
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
872000
CY2018Q4 syn Accrued Clinical Consulting Services
AccruedClinicalConsultingServices
674000
CY2017Q4 syn Accrued Clinical Consulting Services
AccruedClinicalConsultingServices
658000
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
14000
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
919000
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1526000
CY2018Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
907000
CY2017Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
1283000
CY2018Q4 us-gaap Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Current
PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesCurrent
307000
CY2017Q4 us-gaap Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Current
PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesCurrent
590000
CY2018Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
118000
CY2017Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
201000
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1332000
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2074000
CY2018 syn Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumption Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice
0.69
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.86
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0275
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P4Y
CY2018Q4 us-gaap Share Price
SharePrice
0.56
CY2017Q4 us-gaap Share Price
SharePrice
17.85
CY2014Q4 us-gaap Share Price
SharePrice
61.25
CY2018 syn Fair Values Assumptions Expected Dividend Rate
FairValuesAssumptionsExpectedDividendRate
0
CY2017 syn Fair Values Assumptions Expected Dividend Rate
FairValuesAssumptionsExpectedDividendRate
0
CY2014Q4 syn Fair Values Assumptions Expected Dividend Rate
FairValuesAssumptionsExpectedDividendRate
0
CY2017 syn Fair Values Assumptions Expected Volatility Rate
FairValuesAssumptionsExpectedVolatilityRate
0.8
CY2014Q4 syn Fair Values Assumptions Expected Volatility Rate
FairValuesAssumptionsExpectedVolatilityRate
0.95
CY2018 syn Fair Values Assumptions Risk Free Interest Rate
FairValuesAssumptionsRiskFreeInterestRate
0.0260
CY2017 syn Fair Values Assumptions Risk Free Interest Rate
FairValuesAssumptionsRiskFreeInterestRate
0.0186
CY2014Q4 syn Fair Values Assumptions Risk Free Interest Rate
FairValuesAssumptionsRiskFreeInterestRate
0.0139
CY2017 syn Fair Values Assumptions Expected Terms
FairValuesAssumptionsExpectedTerms
P1Y9M14D
CY2014Q4 syn Fair Values Assumptions Expected Terms
FairValuesAssumptionsExpectedTerms
P5Y
CY2016Q4 syn Warrant Liabilities
WarrantLiabilities
14821000
CY2017 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-10738000
CY2017Q4 syn Warrant Liabilities
WarrantLiabilities
4083000
CY2018 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-4083000
CY2018Q4 syn Warrant Liabilities
WarrantLiabilities
0
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
1638333
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
56.00
CY2017 syn Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod
0
CY2017 syn Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue
0
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
723195
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
60.20
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
915138
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
52.50
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
18000713
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.38
CY2018 syn Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod
0
CY2018 syn Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue
0
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
0
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
0
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
18915851
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
3.85
CY2018Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
824000
CY2018 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
CY2017 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
166000
CY2017Q4 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
9000
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.38
CY2018Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
1000
CY2018Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
13672173
CY2018Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
13672173
CY2018Q4 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
1.15
CY2018Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.38
CY2018Q4 syn Percentage Of Issue Of The Public Offering
PercentageOfIssueOfThePublicOffering
120
CY2018Q4 syn Investment Warrants Expiration Date1
InvestmentWarrantsExpirationDate1
2023-10-15
CY2018 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
3500000
CY2018 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
12200000
CY2017 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
11965
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
300000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
309000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
321000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
192000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
1122000
CY2018 us-gaap Proceeds From Repurchase Of Equity
ProceedsFromRepurchaseOfEquity
3000000
CY2018Q4 syn Exchange Percentage Of Unregistered Common Stock
ExchangePercentageOfUnregisteredCommonStock
0.5
CY2016 us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
643000
CY2015 us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
424000
CY2018 us-gaap Line Of Credit Facility Periodic Payment Interest
LineOfCreditFacilityPeriodicPaymentInterest
381150
CY2018 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
201000
CY2017 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
199000
CY2017Q4 us-gaap Payments For Fees
PaymentsForFees
4500000
CY2015 us-gaap Officers Compensation
OfficersCompensation
385000
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
10000000
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
15484411
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15482083
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3673342
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3671014
CY2018 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
272000
CY2017 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
245000
CY2018 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
243000
CY2017 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
73000
CY2018 syn Subsidiary Stock Issues To Vendor
SubsidiaryStockIssuesToVendor
36000
CY2017 syn Subsidiary Stock Issues To Vendor
SubsidiaryStockIssuesToVendor
0
CY2018 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
26000
CY2017 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
0
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7000
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
212000
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-7000
CY2017 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-212000
CY2018 syn Fair Values Assumptions Expected Terms
FairValuesAssumptionsExpectedTerms
P9M14D
CY2019Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
26000000
CY2018Q4 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
16700000
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.2574
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.2574
CY2018Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
42000
CY2017Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
94000
CY2018 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0474
CY2017 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0474
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
0
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Convertible Preferred Stock Terms Of Conversion
ConvertiblePreferredStockTermsOfConversion
The Company may not effect, and holder will not be entitled to, exercise any Warrants or conversion of the Series B Preferred Stock, which, upon giving effect to such exercise, would cause (i) the aggregate number of shares of common stock beneficially owned by the holder (together with its affiliates) to exceed 4.99% (or, at the election of the holder, 9.99%) of the number of shares of common stock outstanding immediately after giving effect to the exercise, or (ii) the combined voting power of the Company's securities beneficially owned by the holder (together with its affiliates) to exceed 4.99% (or, at the election of the holder, 9.99%) of the combined voting power of all of the Company's securities then outstanding immediately after giving effect to the exercise or conversion, as such percentage ownership is determined in accordance with the terms of the October 2018 Warrants or Series B Preferred Stock. However, any holder may increase or decrease such percentage to any other percentage not in excess of 9.99% upon at least 61 days' prior notice from the holder to the Company. The holders of the Series B Preferred will participate, on an as-if-converted-to-common stock basis, in any dividends to the holders of common stock. Upon a defined Fundamental Transaction, the holders of the Series B Preferred Stock are entitled to the same consideration as are holders of common stock. The Series B Preferred Stock ranks junior to existing Series A preferred stock but on parity with common stock. Liquidation preference is equal to an amount pari passu with the common stock on an as converted basis (i.e., there is no preference to common stock)
CY2016Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
2261000
CY2017 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
3409000
CY2017 syn Stock Issued During Period At Market Offering Value
StockIssuedDuringPeriodAtMarketOfferingValue
6346000
CY2017 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
166000
CY2017 syn Adjustments To Additional Paid In Capital Convertible Preferred Stock With Conversion Feature
AdjustmentsToAdditionalPaidInCapitalConvertiblePreferredStockWithConversionFeature
0
CY2017 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
27000
CY2017 us-gaap Dividends Preferred Stock
DividendsPreferredStock
73000
CY2018 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2074000
CY2018 syn Stock Issued During Period At Market Offering Value
StockIssuedDuringPeriodAtMarketOfferingValue
12172000
CY2018 us-gaap Dividends Preferred Stock
DividendsPreferredStock
243000
CY2018 syn Adjustments To Additional Paid In Capital Convertible Preferred Stock With Conversion Feature
AdjustmentsToAdditionalPaidInCapitalConvertiblePreferredStockWithConversionFeature
0
CY2018 syn Conversion Of Series B Preferred Stock To Common Stock
ConversionOfSeriesBPreferredStockToCommonStock
0
CY2018 syn Stock Issued During Period Value Of Syn Biomics Stock
StockIssuedDuringPeriodValueOfSynBiomicsStock
36000
CY2018 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
12172000
CY2017 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
6358000
CY2018 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
4042000
CY2017 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
0
CY2018 us-gaap Dividends Preferred Stock Paidinkind
DividendsPreferredStockPaidinkind
243000
CY2017 us-gaap Dividends Preferred Stock Paidinkind
DividendsPreferredStockPaidinkind
73000
CY2018 syn Fair Values Assumptions Expected Volatility Rate
FairValuesAssumptionsExpectedVolatilityRate
1.1
CY2018 syn Common Stock And Warrants Issued Value To Vendors
CommonStockAndWarrantsIssuedValueToVendors
35000
CY2018 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
16916000
CY2018 dei Document Type
DocumentType
10-K
CY2018 dei Amendment Flag
AmendmentFlag
false
CY2018 dei Document Period End Date
DocumentPeriodEndDate
2018-12-31
CY2018 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
CY2018 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2018 dei Entity Registrant Name
EntityRegistrantName
Synthetic Biologics, Inc.
CY2018 dei Entity Central Index Key
EntityCentralIndexKey
0000894158
CY2018 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2018 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2018 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2018 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2018 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2018Q2 dei Entity Public Float
EntityPublicFloat
27800000
CY2018 dei Trading Symbol
TradingSymbol
SYN
CY2019Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
15484411
CY2018 dei Entity Shell Company
EntityShellCompany
false
CY2018 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2018 dei Entity Small Business
EntitySmallBusiness
true
CY2018Q3 us-gaap Stock Issued During Period Shares Reverse Stock Splits
StockIssuedDuringPeriodSharesReverseStockSplits
128500000
CY2018 us-gaap Stock Issued During Period Shares Reverse Stock Splits
StockIssuedDuringPeriodSharesReverseStockSplits
3700000
CY2018Q3 us-gaap Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
321000
CY2018Q3 us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
321000
CY2018 syn Options To Be Received Common Stock Shares
OptionsToBeReceivedCommonStockShares
2000000
CY2017 us-gaap Proceeds From Repurchase Of Equity
ProceedsFromRepurchaseOfEquity
3000000
CY2018Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
102000
CY2018Q3 syn Fair Value Of Shares Issued
FairValueOfSharesIssued
285000

Files In Submission

Name View Source Status
0001144204-19-010592-index-headers.html Edgar Link pending
0001144204-19-010592-index.html Edgar Link pending
0001144204-19-010592.txt Edgar Link pending
0001144204-19-010592-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
syn-20181231.xml Edgar Link completed
syn-20181231.xsd Edgar Link pending
syn-20181231_cal.xml Edgar Link unprocessable
syn-20181231_def.xml Edgar Link unprocessable
syn-20181231_lab.xml Edgar Link unprocessable
syn-20181231_pre.xml Edgar Link unprocessable
tv513906_10k.htm Edgar Link pending
tv513906_ex21.htm Edgar Link pending
tv513906_ex23-1.htm Edgar Link pending
tv513906_ex31-1.htm Edgar Link pending
tv513906_ex32-1.htm Edgar Link pending
tv513906_img04.jpg Edgar Link pending
tv513906_img05.jpg Edgar Link pending